PMID- 20006667
OWN - NLM
STAT- MEDLINE
DCOM- 20100907
LR  - 20211203
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 71
IP  - 3
DP  - 2010 Mar
TI  - Liver transplant recipients weaned off immunosuppression lack circulating 
      donor-specific antibodies.
PG  - 274-6
LID - 10.1016/j.humimm.2009.12.002 [doi]
AB  - Human leukocyte antigen (HLA)-specific antibodies (Abs) were examined in 73 
      clinically stable liver transplant recipients divided into group A (n = 19; 
      clinically tolerant), group B (n = 34; undergoing weaning, on minimal 
      immunosuppression), and group C (n = 20; had failed drug withdrawal or weaning 
      never attempted). Of 19 patients in group A, six (32%) had anti-HLA Abs; none 
      were donor-specific. In contrast, 23 of 34 patients (67%) in group B and nine of 
      20 patients (45%) in group C exhibited anti-HLA Abs (p = 0.02). Furthermore, 15 
      of 19 patients in groups B and C (9/12, p = 0.01 and 6/7, p = 0.01, respectively) 
      exhibited donor-specific anti-HLA Abs. The prevalence of donor-specific HLA Abs 
      was significantly higher in nontolerant patients. Five years after initial 
      evaluation, >90% (18/19) group A patients remained off immunosuppression. One of 
      seven of these patients available for retesting exhibited donor-specific Abs. In 
      group B, two-fourths of 34 patients (12%) weaned successfully were HLA-Ab 
      negative; four patients who experienced rejection while undergoing weaning 
      exhibited anti-HLA Ab initially and at 5 years. Thus, most of the liver 
      recipients off immunosuppression lacked donor-specific alloAbs. The occurrence of 
      these alloAbs should now be examined prospectively in a drug weaning trial.
CI  - (c) 2010 American Society for Histocompatibility and Immunogenetics. Published by 
      Elsevier Inc. All rights reserved.
FAU - Girnita, Alin
AU  - Girnita A
AD  - Thomas E. Starzl Transplantation Institute and Department of Pathology, 
      University of Pittsburgh School of Medicine and Children's Hospital of 
      Pittsburgh, Pennsylvania, USA.
FAU - Mazariegos, George V
AU  - Mazariegos GV
FAU - Castellaneta, Antonino
AU  - Castellaneta A
FAU - Reyes, Jorge
AU  - Reyes J
FAU - Bentlejewski, Carol
AU  - Bentlejewski C
FAU - Thomson, Angus W
AU  - Thomson AW
FAU - Zeevi, Adriana
AU  - Zeevi A
LA  - eng
GR  - P01 AI81678/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20091223
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies/blood
MH  - Child
MH  - Child, Preschool
MH  - Follow-Up Studies
MH  - Graft Rejection/*diagnosis/epidemiology/*immunology/physiopathology
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Immunosuppression Therapy
MH  - *Liver Transplantation
MH  - Middle Aged
MH  - Prevalence
MH  - Prognosis
MH  - Tissue Donors
MH  - Transplantation Tolerance
MH  - Withholding Treatment
EDAT- 2009/12/17 06:00
MHDA- 2010/09/08 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/11/24 00:00 [received]
PHST- 2009/11/24 00:00 [revised]
PHST- 2009/12/02 00:00 [accepted]
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/09/08 06:00 [medline]
AID - S0198-8859(09)00656-9 [pii]
AID - 10.1016/j.humimm.2009.12.002 [doi]
PST - ppublish
SO  - Hum Immunol. 2010 Mar;71(3):274-6. doi: 10.1016/j.humimm.2009.12.002. Epub 2009 
      Dec 23.